Colorectal Cancer

During the 2022 American Society of Clinical Oncology Annual Meeting, Richard Kim, MD, discusses the rationale for the phase 1b KEYNOTE-651 trial examining pembrolizumab plus chemotherapy in metastatic colorectal cancer.

Adding irinotecan to chemotherapy plus panitumumab for treatment of metastatic colorectal cancer did not result in a significant impact on efficacy.

In patients with colorectal cancer and synchronous unresectable metastases, resection of the primary tumor before systemic therapy did not result in an extension of overall survival.

Bevacizumab plus FOLFOXIRI was superior to bevacizumab plus FOLFOX or FOLFIRI in terms of efficacy but was more toxic in certain patients with initially unresectable colorectal cancer liver metastases.

Superior efficacy was observed when patients with RAS wild–type metastatic colorectal cancer were treated with panitumumab plus chemotherapy vs bevacizumab in the first-line setting.

Atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and irinotecan resulted in a tolerable safety profile and improved progression-free survival vs the control regimen in patients with metastatic colorectal cancer.

Drs. Cohen and Lewis close by outlining ongoing clinical trials in CRC and hopes for the future of care.

Stacy A. Cohen, MD and Mark Lewis, MD share key takeaways from the GALAXY study and discuss the clinical implications of using ctDNA-based assays for patients with CRC.

Experts describe cumulative ctDNA clearance rates in patients with stage I-IV disease who did or did not receive adjuvant chemotherapy in the GALAXY study.

In the phase 2 MOUNTAINEER trial, patients with previously treated HER2-positive metastatic colorectal cancer who were treated with tucatinib plus trastuzumab were shown to have an improved objective response rate.

Tanios Bekaii-Saab, MD, talks with Kristen Ciombor, MD, MSCI, and John Strickler, MD, about targeted therapy resistance, rechallenge, and acquired resistance mutations in colorectal cancer.

Stacy A. Cohen, MD, and Mark Lewis, MD, discuss how DFS correlates with stage and adjuvant chemotherapy receipt in patients who are ctDNA-positive.

GI oncologists discuss DFS data from the dynamics analysis cohort of the GALAXY study.

Data from a large-scale population-based case control study indicated that excessive weight could have a notably higher odds ratio of CRC risk than previously identified in epidemiologic studies.

Mark Lewis, MD, provides a historical perspective of circulating tumor DNA and discusses previous trials on ctDNA analysis in patients with CRC.

Stacy A. Cohen, MD, and Mark Lewis, MD, comment on disease-free survival rates by ctDNA status in patients enrolled in the GALAXY study.

Despite having a good rate of treatment adherence, patients who are diagnosed with high-risk stage III colorectal cancer at a younger age may have higher rates of relapse.

Drs Cohen and Lewis review the GALAXY enrollment strategy and describe the various colorectal cancer patient cohorts in the study.

Stacey A. Cohen, MD, and Mark Lewis, MD, introduce the 2022 ASCO GI abstract, “Association of Circulating Tumor DNA Dynamics With Clinical Outcomes in the Adjuvant Setting for Patients With Colorectal Cancer From an Observational GALAXY Study in CIRCULATE-Japan.”

Patients with KRAS G12C-mutated colorectal cancer treated with sotorasib showed modest anti-tumor activity during a phase 2 trial.

Liliana Bustamante, MD, and Richard Kim, MD, discuss circulating tumor DNA as a potential prognostic biomarker for patients with colorectal cancer.

In an interview with CancerNetwork® during National Colorectal Cancer Awareness Month, Rachel Pearlman, MS, LGC, highlights recent updates in genetic testing in colorectal cancer and where the field needs to head to provide individuals with better options.

Tanios Bekaii-Saab, MD; Kristen Ciombor, MD, MSCI; and John Strickler, MD, detail key developments and needs in the gastrointestinal cancers landscape.

A clinical hold has been placed on the phase 1b CYAD-101-002 trial, examining pembrolizumab after treatment with CYAD-101 and folinic acid, fluorouracil, and oxaliplatin preconditioning in metastatic colorectal cancer.

This review article written by Nikia R. McFadden, MD, MAS, et al, discusses which therapies are best to treat unresectable colorectal liver metastases.